Xenon Pharmaceuticals Inc. (XENE:NASDAQ) closed at $35.77 on October 26, 2026, up 1.22% on the day. The stock trades 50.8% below its 52-week high of $72.66 and 7.2% above its 52-week low of $33.38. Over the past year, it lost 13.3%. Xenon Pharmaceuticals Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 24, 2025, XENE closed higher on 115 days (46%). Its best day was March 9, 2026 (+49.64%) and its worst was September 18, 2026 (-30.69%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its preclinical product candidate includes XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of childhood epilepsy disorders. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd.; Genentech, Inc.; uniQure Biopharma B.V.; and Merck & Co., In...
Find more stocks like XENE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.